Company intelligence / Profile preview

Karo Healthcare

Ownership: Private
Employees: ~460
Development stage: Commercial

Overview

Karo Healthcare commercializes a broad portfolio of branded over-the-counter and prescription products across Europe and more than ninety countries. The company focuses on established brands with documented efficacy in everyday healthcare categories. No recent clinical trial results are highlighted as the business model centers on commercialization rather than new drug development.

Therapeutic areas: PulmonologyOtherDermatologyGastroenterologyNeurologyWomen's Health
Modalities: Small moleculeBiologicDeviceVitamin & Mineral Supplements
Industry: Consumable Medical Devices

Drug pipeline

3 assets

Lamisil

Commercial

Indications: Foot health, Fungal infections

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Karo Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Karo Healthcare.

Explore the full profile